Mirabegron + Placebo

Phase 3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cystitis, Interstitial

Conditions

Cystitis, Interstitial

Trial Timeline

Aug 1, 2016 → Jul 5, 2019

NCT ID

NCT02787083

About Mirabegron + Placebo

Mirabegron + Placebo is a phase 3 stage product being developed by Astellas Pharma for Cystitis, Interstitial. The current trial status is terminated. This product is registered under clinical trial identifier NCT02787083. Target conditions include Cystitis, Interstitial.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04641975	Phase 3	Terminated	Mar 15, 2021	Jul 24, 2023	Overactive Bladder (OAB)
NCT02787083	Phase 3	Terminated	Aug 1, 2016	Jul 5, 2019	Cystitis, Interstitial
NCT02216214	Approved	Completed	Oct 7, 2014	Jan 2, 2018	Overactive Bladder (OAB)
NCT02086188	Approved	Completed	May 1, 2014	Jun 1, 2019	Multiple Sclerosis
NCT02092181	Approved	Completed	Mar 1, 2014	Jul 1, 2018	Parkinsons Disease
NCT01284309	Phase 1	Completed	Nov 1, 2010	Feb 1, 2011	Intraocular Pressure
NCT00912964	Phase 3	Completed	Apr 28, 2009	Apr 27, 2010	Urinary Bladder, Overactive
NCT00662909	Phase 3	Completed	Mar 28, 2008	Apr 22, 2009	Urinary Bladder, Overactive
NCT00410514	Phase 2	Completed	Dec 1, 2006	Aug 1, 2008	Lower Urinary Tract Symptoms

Competing Products

19 competing products in Cystitis, Interstitial

See all competitors

Product	Company	Stage	Hype Score
Ferumoxytol + Gadobutrol	Lipella Pharmaceuticals	Phase 1	25
LP-10	Lipella Pharmaceuticals	Phase 2	44
LP-08 80mg + Normal saline + LP-08 20mg	Lipella Pharmaceuticals	Phase 2	44
ASP3652 + Placebo	Astellas Pharma	Phase 2	52
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	52
Placebo + JNJ-42160443	Johnson & Johnson	Phase 2	52
Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mg	Johnson & Johnson	Approved	85
BOTOX + Placebo for BOTOX	AbbVie	Phase 2	52
Rocuronium	Merck	Approved	85
Cidofovir	Gilead Sciences	Pre-clinical	22
PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685	Pfizer	Phase 2	51
Tanezumab + Tanezumab + Tanezumab + Tanezumab	Pfizer	Phase 2	51
ERB-041	Pfizer	Pre-clinical	22
PF-04383119 + Placebo	Pfizer	Phase 2	51
Certolizumab pegol + Placebo	UCB	Phase 3	74
moxifloxacin	Bayer	Phase 3	74
Cipro (Ciprofloxacin, BAYQ3939)	Bayer	Pre-clinical	20
IW-3300 rectal foam + Placebo	Ironwood Pharmaceuticals	Phase 2	44
MN-001 BID + MN-001 + Placebo	MediciNova	Phase 2	44

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved